Dermira begins phase 3 programme to assess lebrikizumab in patients with moderate-to-severe atopic dermatitis

Image: Dermira has started phase 3 programme to assess lebrikizumab in patients with moderate-to-severe atopic dermatitis. Photo: courtesy of Hans Braxmeier from Pixabay.